HOME >> BIOLOGY >> NEWS
Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

The number of lymph nodes that contain evidence of cancer is the best predictor of the effectiveness of adding chemotherapy and radiation to a treatment plan prior to surgery in individuals with oesophageal cancer, according to a study published last month in the Annals of Surgery. The authors say their finding is particularly important because the focus of recent pathological studies of response to neoadjuvant therapies has been on the primary tumour rather than nodal sites.

Multimodal neoadjuvant therapy---where suitable patients are given several cycles of drugs and radiation therapy before undergoing surgical procedures to remove their tumour---is increasingly being used by oncologists as a way to boost survival rates from oesophageal cancer which, even with the most radical surgery, remain low: only 50% of patients survive for 3 years. However, the evidence for which additional therapies work best is confusing and conflicting. What is more, although it is widely accepted that there is a group of patients in whom this approach works well, identifying who these patients are is no easy task.

To help find ways of pinpointing individuals who might respond best to neoadjuvant treatment, John Vincent Reynolds and colleagues followed the progress of 243 patients who were treated with chemotherapy and radiation before surgery over 5 years. They paid particular attention to the histomorphological responses of patients---changes in the structure and appearance of tissue samples when viewed under a microscope---in addition to assessing prognosis using the traditional TNM method of staging, which takes into account tumour size, involvement of lymph nodes (nodal status), and presence or absence of metastases.

The study group consisted of all patients undergoing neoadjuvant treatment for oesophageal cancer at St James Hospital in Dublin,Ireland. Patients with oesophageal cancer were deemed suitable for multimodal therapy if they fulfilled
'"/>

Contact: Corinne Hall
mediaservice@esoncology.org
39-028-546-4522
European School of Oncology
13-Jul-2007


Page: 1 2 3

Related biology news :

1. MU researchers to study the status of black bears in Missouri
2. Green sturgeon receives threatened status
3. High-status monkeys ignore the interests of riff-raff
4. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible status
5. Sudden change in social status triggers genetic response in male fish, study finds
6. Manatee eyes could be window to health status
7. Location, location, location: Effect of nuclear organization on transcriptional status
8. Biologists findings on fertility and status in monkeys generate scientific, media interest
9. MIDI, Inc receives Official Methods(SM) status for the confirmatory ID of the anthrax pathogen
10. Study in Royal Society journal on how relationship status influences sex ratios
11. DNA highly promising predictor for successful treatment of alcoholics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... ... voice recognition biometrics market to grow at a CAGR of 19.36% ... present scenario and the growth prospects of the global voice recognition ... considers the revenue generated from the sales of voice recognition biometrics ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... , ... February 27, 2017 , ... The Catalyst ... a few in the Midwest offering premix services and private label organic services. , ... laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, which owns the ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... be safely completed in an ambulatory surgery center (ASC) with satisfactory clinical and ... previous two-year TDR studies. , Jake Lubinski, president of AxioMed, commented on ...
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... 24, 2017  Driven by consumers, preference towards ... the fastest growing categories, finds the recently published ... Personal Care: Multi-regional Market Analysis and Opportunities ... firm Kline. "Biotechnology actives are derived ... more effective for skin and hair care applications," ...
Breaking Biology Technology:
Cached News: